<DOC>
	<DOC>NCT01720290</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to compare repaglinide and metformin administered alone or in combination in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Previously treated with oral hypoglycaemic agents (OHA) as monotherapy (if metformin, less than 1500 mg daily) Body Mass Index (BMI) of 2135 kg/m^2 HbA1c (glycosylated haemoglobin A1c) between 7.010% Treatment with insulin within the last 3 months preceding the trial Uncontrolled treated or untreated hypertension (systolic blood pressure above or equal to 180 mm Hg, and/or diastolic blood pressure above 105 mm Hg) Participation in any other clinical trial within 30 days of screening</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>